Fzata

Fzata is developing a novel oral biologics platform, BioPYM®, which utilizes engineered probiotic yeast to produce therapeutics locally in the gut, aiming to treat gastrointestinal diseases without injections. The company is advancing toward its first-in-human clinical trials targeted for summer 2026, pending FDA clearance, and is preparing for a Series A financing round. With strong academic roots and over $24 million in non-dilutive NIH funding, Fzata is led by a team of scientific founders and industry veterans, positioning itself to address significant unmet needs in conditions like C. difficile infection.

Bioengineered Probiotic Yeast Medicines (BioPYM®): A platform using live, engineered Saccharomyces cerevisiae yeast as in-situ micro-factories to produce and deliver therapeutic proteins (antibodies, enzymes, cytokines) orally, targeting the gastrointestinal tract.

Fzata competes with other companies developing oral biologics and live biotherapeutic products for GI diseases, including those using bacterial vectors or alternative delivery technologies. In CDI, it faces competition from systemic antibody drugs (e.g., bezlotoxumab) and microbiome-based therapies, but its localized, yeast-based production approach is a distinct differentiator.